Skip to main content
Erschienen in: Endocrine 1/2010

01.08.2010 | Case Report

A case of fugitive acromegaly, initially presented as invasive prolactinoma

verfasst von: Jung Soo Lim, Cheol Ryong Ku, Mi-Kyung Lee, Tai Seung Kim, Sun Ho Kim, Eun Jig Lee

Erschienen in: Endocrine | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Fugitive acromegaly is most commonly caused by pituitary acidophil stem cell adenomas, and is characterized by a relatively short clinical history, a large and locally invasive tumor, and relatively low hormonal activity. Here, we report an unusual case of fugitive acromegaly that initially presented as invasive prolactinoma. A 48-year-old man with a huge pituitary mass extending to the suprasellar area was referred to our hospital in December 2007. He had undergone transsphenoidal surgery in November 1999 because of a large invasive prolactinoma. The tumor had grown progressively, despite therapy with dopamine agonists. Subtle features of acromegaly were noted and serum IGF-1 levels were high (733 ng/ml). An oral glucose tolerance test revealed that basal and nadir levels of growth hormone (GH) were 1.56 and 1 ng/ml, respectively. As a therapeutic trial, long-acting octreotide (20 mg IM, monthly) was added, and the tumor size markedly reduced within 6 months on magnetic resonance imaging examination. Immunohistochemical staining of the tumor tissue obtained at the surgery in 1999 showed positive staining for GH and prolactin (PRL). Double immunofluorescence staining showed a mixed positivity for GH and PRL in the majority of tumor cells; however, the two hormones colocalized in a minority of tumor cells, indicating that the tumor was composed of three different cell types (GH, PRL, and GH/PRL). The diagnosis of fugitive acromegaly was initially overlooked in this patient because of normal serum GH levels and a lack of acromegalic features, although histological evidence for GH production was present. IGF-1 determinations would be helpful for the diagnosis of fugitive acromegaly.
Literatur
2.
Zurück zum Zitat A. Avramidis, S.A. Polyzos, Z. Efstathiadou, M. Kita, Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatment. Endocr. J. 55(2), 351–357 (2008)CrossRefPubMed A. Avramidis, S.A. Polyzos, Z. Efstathiadou, M. Kita, Sustained clinical inactivity and stabilization of GH/IGF-1 levels in an acromegalic patient after discontinuation of somatostatin analogue treatment. Endocr. J. 55(2), 351–357 (2008)CrossRefPubMed
3.
Zurück zum Zitat E. Horvath, K. Kovacs, W. Singer, H.S. Smyth, D.W. Killinger, C. Erzin, M.H. Weiss, Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47(4), 761–771 (1981)CrossRefPubMed E. Horvath, K. Kovacs, W. Singer, H.S. Smyth, D.W. Killinger, C. Erzin, M.H. Weiss, Acidophil stem cell adenoma of the human pituitary: clinicopathologic analysis of 15 cases. Cancer 47(4), 761–771 (1981)CrossRefPubMed
4.
Zurück zum Zitat W. Saeger, D.K. Ludecke, M. Buchfelder, R. Fahlbusch, H.J. Quabbe, S. Petersenn, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156(2), 203–216 (2007)CrossRefPubMed W. Saeger, D.K. Ludecke, M. Buchfelder, R. Fahlbusch, H.J. Quabbe, S. Petersenn, Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur. J. Endocrinol. 156(2), 203–216 (2007)CrossRefPubMed
5.
Zurück zum Zitat H.G. Maheshwari, T.R. Prezant, V. Herman-Bonert, H. Shahinian, K. Kovacs, S. Melmed, Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J. Clin. Endocrinol. Metab. 85(9), 3409–3416 (2000)CrossRefPubMed H.G. Maheshwari, T.R. Prezant, V. Herman-Bonert, H. Shahinian, K. Kovacs, S. Melmed, Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J. Clin. Endocrinol. Metab. 85(9), 3409–3416 (2000)CrossRefPubMed
6.
Zurück zum Zitat S.L. Asa, K. Kovacs, E. Horvath, W. Singer, H.S. Smyth, Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line. J. Clin. Endocrinol. Metab. 75(1), 68–75 (1992)CrossRefPubMed S.L. Asa, K. Kovacs, E. Horvath, W. Singer, H.S. Smyth, Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line. J. Clin. Endocrinol. Metab. 75(1), 68–75 (1992)CrossRefPubMed
8.
Zurück zum Zitat G. Mohr, Z.P. Chen, M. Schweitzer, Acromegaly with normal basal growth hormone levels. Can. J. Neurol. Sci. 24(3), 250–253 (1997)PubMed G. Mohr, Z.P. Chen, M. Schweitzer, Acromegaly with normal basal growth hormone levels. Can. J. Neurol. Sci. 24(3), 250–253 (1997)PubMed
9.
Zurück zum Zitat B. Swearingen, F.G. Barker 2nd, L. Katznelson, B.M. Biller, S. Grinspoon, A. Klibanski, N. Moayeri, P.M. Black, N.T. Zervas, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83(10), 3419–3426 (1998)CrossRefPubMed B. Swearingen, F.G. Barker 2nd, L. Katznelson, B.M. Biller, S. Grinspoon, A. Klibanski, N. Moayeri, P.M. Black, N.T. Zervas, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J. Clin. Endocrinol. Metab. 83(10), 3419–3426 (1998)CrossRefPubMed
10.
Zurück zum Zitat D.R. Clemmons, J.J. Van Wyk, E.C. Ridgway, B. Kliman, R.N. Kjellberg, L.E. Underwood, Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N. Engl. J. Med. 301(21), 1138–1142 (1979)CrossRefPubMed D.R. Clemmons, J.J. Van Wyk, E.C. Ridgway, B. Kliman, R.N. Kjellberg, L.E. Underwood, Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N. Engl. J. Med. 301(21), 1138–1142 (1979)CrossRefPubMed
11.
Zurück zum Zitat A. Colao, R. Pivonello, R.S. Auriemma, M.C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I.A. Kourides, C.J. Strasburger, G. Lombardi, Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154(3), 467–477 (2006)CrossRefPubMed A. Colao, R. Pivonello, R.S. Auriemma, M.C. De Martino, M. Bidlingmaier, F. Briganti, F. Tortora, P. Burman, I.A. Kourides, C.J. Strasburger, G. Lombardi, Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur. J. Endocrinol. 154(3), 467–477 (2006)CrossRefPubMed
12.
Zurück zum Zitat C.E. Higham, T.T. Chung, J. Lawrance, W.M. Drake, P.J. Trainer, Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 71(1), 86–91 (2009)CrossRef C.E. Higham, T.T. Chung, J. Lawrance, W.M. Drake, P.J. Trainer, Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 71(1), 86–91 (2009)CrossRef
13.
Zurück zum Zitat M. Gradiser, M. Matovinovic, M. Vrkljan, Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat. Med. J. 48(1), 87–91 (2007)PubMed M. Gradiser, M. Matovinovic, M. Vrkljan, Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. Croat. Med. J. 48(1), 87–91 (2007)PubMed
14.
Zurück zum Zitat A.P. Heaney, M. Fernando, S. Melmed, PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 111(9), 1381–1388 (2003)PubMed A.P. Heaney, M. Fernando, S. Melmed, PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 111(9), 1381–1388 (2003)PubMed
15.
Zurück zum Zitat G.J. Kaptain, N.E. Simmons, T.D. Alden, M.B. Lopes, M.L. Vance, E.R. Laws, Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1(2), 91–98 (1999)CrossRefPubMed G.J. Kaptain, N.E. Simmons, T.D. Alden, M.B. Lopes, M.L. Vance, E.R. Laws, Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1(2), 91–98 (1999)CrossRefPubMed
16.
Zurück zum Zitat S.W. Lamberts, L.J. Hofland, Future treatment strategies of aggressive pituitary tumors. Pituitary 12(3), 261–264 (2009)CrossRefPubMed S.W. Lamberts, L.J. Hofland, Future treatment strategies of aggressive pituitary tumors. Pituitary 12(3), 261–264 (2009)CrossRefPubMed
17.
Zurück zum Zitat B. Caronti, G. Palladini, M.G. Bevilacqua, E. Petrangeli, B. Fraioli, G. Cantore, G. Tamburrano, C.M. Carapella, M.L. Jaffrain-Rea, Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors. Tumour Biol. 14(1), 59–68 (1993)CrossRefPubMed B. Caronti, G. Palladini, M.G. Bevilacqua, E. Petrangeli, B. Fraioli, G. Cantore, G. Tamburrano, C.M. Carapella, M.L. Jaffrain-Rea, Effects of 17 beta-estradiol, progesterone and tamoxifen on in vitro proliferation of human pituitary adenomas: correlation with specific cellular receptors. Tumour Biol. 14(1), 59–68 (1993)CrossRefPubMed
18.
Zurück zum Zitat I. Vourliotaki, I.E. Bonapart, C. Stamataki, E.M. Tsapakis, C. Saridaki, A case of a prolactinoma resistant to dopamine agonists. Hormones (Athens) 4(3), 165–170 (2005) I. Vourliotaki, I.E. Bonapart, C. Stamataki, E.M. Tsapakis, C. Saridaki, A case of a prolactinoma resistant to dopamine agonists. Hormones (Athens) 4(3), 165–170 (2005)
19.
Zurück zum Zitat G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.G. Ren, S. Melmed, Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 68(15), 6377–6386 (2008)CrossRefPubMed G. Vlotides, E. Siegel, I. Donangelo, S. Gutman, S.G. Ren, S. Melmed, Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res. 68(15), 6377–6386 (2008)CrossRefPubMed
20.
Zurück zum Zitat E. Gutteridge, A. Agrawal, R. Nicholson, K.L. Cheung, J. Robertson, J. Gee, The effects of gefitinib in tamoxifen resistant and hormone insensitive breast cancer: a phase II study. Int. J. Cancer. 126(8), 1806–1816 (2010)PubMed E. Gutteridge, A. Agrawal, R. Nicholson, K.L. Cheung, J. Robertson, J. Gee, The effects of gefitinib in tamoxifen resistant and hormone insensitive breast cancer: a phase II study. Int. J. Cancer. 126(8), 1806–1816 (2010)PubMed
21.
Zurück zum Zitat K. Kageyama, T. Nigawara, Y. Kamata, T. Takahashi, J. Anzai, S. Suzuki, Y.R. Osamura, T. Suda, A case of macroprolactinoma with subclinical growth hormone production. Endocr. J. 49(1), 41–47 (2002)CrossRefPubMed K. Kageyama, T. Nigawara, Y. Kamata, T. Takahashi, J. Anzai, S. Suzuki, Y.R. Osamura, T. Suda, A case of macroprolactinoma with subclinical growth hormone production. Endocr. J. 49(1), 41–47 (2002)CrossRefPubMed
Metadaten
Titel
A case of fugitive acromegaly, initially presented as invasive prolactinoma
verfasst von
Jung Soo Lim
Cheol Ryong Ku
Mi-Kyung Lee
Tai Seung Kim
Sun Ho Kim
Eun Jig Lee
Publikationsdatum
01.08.2010
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2010
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9341-5

Weitere Artikel der Ausgabe 1/2010

Endocrine 1/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.